Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.

Clinical Theragnostic Signature of Extracellular Vesicles in Traumatic Brain Injury (TBI)

Open access

Abstract

Traumatic brain injury (TBI) is a common cause of disability and fatality worldwide. Depending on the clinical presentation, it is a type of acquired brain damage that can be mild, moderate, or severe. The degree of patient's discomfort, prognosis, therapeutic approach, survival rates, and recurrence can all be strongly impacted by an accurate diagnosis made early on. The Glasgow Coma Scale (GCS), along with neuroimaging (MRI (Magnetic Resonance Imaging) and CT scan), is a neurological assessment tools used to evaluate and categorize the severity of TBI based on the patient's level of consciousness, eye opening, and motor response. Extracellular vesicles (EVs) are a growing domain, explaining neurological complications in a more detailed manner. EVs, in general, play a role in cellular communication. Its molecular signature such as DNA, RNA, protein, etc. contributes to the status (health or pathological stage) of the parental cell. Brain-derived EVs support more specific screening (diagnostic and prognostic) in TBI research. Therapeutic impact of EVs are more promising for aiding in TBI healing. It is nontoxic, biocompatible, and capable of crossing the blood-brain barrier (BBB) to transport therapeutic molecules. This review has highlighted the relationships between EVs and TBI theranostics, EVs and TBI-related clinical trials, and related research domain-associated challenges and solutions. This review motivates further exploration of associations between EVs and TBI and develops a better approach to TBI management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acschemneuro.3c00386

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Interlink between EVs and brain function. (Created with BioRender.com).
Figure 1 Interlink between EVs and brain function. (Created with BioRender.com).CC BY · PubMed Central
Figure 2 TBI secondary pathophysiology mechanism highlighting exosomal signal transduction via the apoptotic body endocytic pathway. Exosome secretory processes from apoptotic cell death after primary TBI cause secondary mechanisms of TBI and have a detrimental impact by impacting axon demyelination by transport protein accumulation and, ultimately, neuron cell death. Overall, signaling occurs via miRNAs and dysregulation of mRNA splicing mechanisms, resulting in unwanted protein accumulation in the axon and damage to the myelin sheath with demyelination processes, which result in different protein dysregulation and additional conditions that lead to: Ca2+ → mitochondria → ROS (reactive oxygen species) → caspases → DNA damage → cell death. (Created with BioRender.com).
Figure 2 TBI secondary pathophysiology mechanism highlighting exosomal signal transduction via the apoptotic body endocytic pathway. Exosome secretory processes from apoptotic cell death after primary TBI cause secondary mechanisms of TBI and have a detrimental impact by impacting axon demyelination by transport protein accumulation and, ultimately, neuron cell death. Overall, signaling occurs via miRNAs and dysregulation of mRNA splicing mechanisms, resulting in unwanted protein accumulation in the axon and damage to the myelin sheath with demyelination processes, which result in different protein dysregulation and additional conditions that lead to: Ca2+ → mitochondria → ROS (reactive oxygen species) → caspases → DNA damage → cell death. (Created with BioRender.com).CC BY · PubMed Central
Figure 3 Exosome biogenesis and its molecular component. (Adapted with permission from ref (127). Copyright 2022 American Chemical Society).
Figure 3 Exosome biogenesis and its molecular component. (Adapted with permission from ref (127). Copyright 2022 American Chemical Society).CC BY · PubMed Central
Figure 4 Interrelation of extracellular vesicles (EVs) and the central nervous system (CNS). (Adapted with permission from ref (66). Copyright licensed under a Creative Commons Attribution 4.0 International License, 2022, Stem Cell Research & Therapy, BMC).
Figure 4 Interrelation of extracellular vesicles (EVs) and the central nervous system (CNS). (Adapted with permission from ref (66). Copyright licensed under a Creative Commons Attribution 4.0 International License, 2022, Stem Cell Research & Therapy, BMC).CC BY · PubMed Central
Figure 5 EV-based TBI biomarkers profiling. (Created with BioRender.com).
Figure 5 EV-based TBI biomarkers profiling. (Created with BioRender.com).CC BY · PubMed Central
Figure 6 Therapeutic activity of mesenchymal stem cell-derived exosomes in TBI (treatment with exosomes derived from MSCs (mesenchymal stem cells)) significantly increases brain vascular density and angiogenesis in rats after TBI. EBA (endothelial barrier antigen) staining was performed for detection of mature vasculature at day 35 after TBI in the lesion boundary zone and dentate gyrus (DG) of the sham group (A and D), PBS-treated group (B and E), and exosome-treated group (C and F). Double staining for EBA (H, green) and BrdU (5-bromo-2′-deoxyuridine) (I, red arrows) to identify newly formed mature vessels (J, yellow arrows) in the brain at day 35 after TBI. Treatment with exosomes derived from MSCs significantly increased cell proliferation and neurogenesis in the DG of rats sacrificed at day 35 after TBI. BrdU staining for cell proliferation (L–Q, black arrows). DCX (doublecortin) staining for immature neurons (P–S, black arrows for DCX+ cells, and pink arrows for dendrites). Double staining with BrdU (red)/DCX (green) for newborn immature neurons is indicated by yellow arrows (T–W, pink arrows for dendrites). BrdU (red)/NeuN (green) for newborn mature neurons (X–Z, yellow arrows) are also labeled. (Adapted with permission from ref (100). Copyright licensed under a Creative Commons Public Domain Mark 1.0., 2015, J Neurosurg.).
Figure 6 Therapeutic activity of mesenchymal stem cell-derived exosomes in TBI (treatment with exosomes derived from MSCs (mesenchymal stem cells)) significantly increases brain vascular density and angiogenesis in rats after TBI. EBA (endothelial barrier antigen) staining was performed for detection of mature vasculature at day 35 after TBI in the lesion boundary zone and dentate gyrus (DG) of the sham group (A and D), PBS-treated group (B and E), and exosome-treated group (C and F). Double staining for EBA (H, green) and BrdU (5-bromo-2′-deoxyuridine) (I, red arrows) to identify newly formed mature vessels (J, yellow arrows) in the brain at day 35 after TBI. Treatment with exosomes derived from MSCs significantly increased cell proliferation and neurogenesis in the DG of rats sacrificed at day 35 after TBI. BrdU staining for cell proliferation (L–Q, black arrows). DCX (doublecortin) staining for immature neurons (P–S, black arrows for DCX+ cells, and pink arrows for dendrites). Double staining with BrdU (red)/DCX (green) for newborn immature neurons is indicated by yellow arrows (T–W, pink arrows for dendrites). BrdU (red)/NeuN (green) for newborn mature neurons (X–Z, yellow arrows) are also labeled. (Adapted with permission from ref (100). Copyright licensed under a Creative Commons Public Domain Mark 1.0., 2015, J Neurosurg.).CC BY · PubMed Central
Figure 7 Single EV profiling approach. (Adapted with permission from ref (115). Copyright 2022 American Chemical Society).
Figure 7 Single EV profiling approach. (Adapted with permission from ref (115). Copyright 2022 American Chemical Society).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 5

  1. 10.4103/0253-7176.203129 · DOI · Paper page
  2. 10.1016/S1474-4422(19)30282-0 · DOI · Paper page
  3. 10.1242/DMM.011585/261894 · doi:10.1242/dmm.011585/261894
  4. 10.3389/FNEUR.2021.698206 · DOI
  5. 10.1016/j.ijsu.2022.106886 · DOI

Cited by

See all 16

Metadata

Authors
Dey, A., Ghosh, S., Bhuniya, T., Koley, M., Bera, A., Guha, S., Chakraborty, K., Muthu, S., Gorai, S., Vorn, R., Vadivalagan, C., & Anand, K.
Affiliations
  • Indian Institute of Technology Guwahati (IN)
  • Indian Institute of Technology Madras (IN)
  • National Institute of Technology Durgapur (IN)
  • Indian Institute of Technology Dhanbad (IN)
  • Heritage Institute of Technology (IN)
  • Orthopaedic Research Group (IN)
  • Rush University Medical Center (US)
  • Johns Hopkins University (US)
  • University of Michigan (US)
  • University of the Free State (ZA)
Corresponding author
Anand, Krishnan
Venue
ACS Chemical Neuroscience
Published
2023-08-25
Volume
14
Issue
17
Pages
2981-2994
ISSN
1948-7193 (ISSN-L)
OpenAlex
W4386153870
Cited by
16
References
123
Citations by year
2026: 3 · 2025: 7 · 2024: 5 · 2023: 1
FWCI
0.42
Type
journal article
Language
en
Open access
Locations
  • ACS Chemical Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Research Foundation (132377)
  • Universiteit van die Vrystaat
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury and Neurovascular Disturbances
  • Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
Keywords
traumatic brain injury, extracellular vesicles, theranostics, biomarkers, TBI diagnosis, prognosis, blood-brain barrier, cell-to-cell communication, neuroinflammation
MeSH terms
Extracellular Vesicles, Brain Injuries, Traumatic, Blood-Brain Barrier, Brain, Brain Injuries, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.